Mesenchymal stem cells and IL-37: a powerful combination

A. Gugliandolo, AL. Caraffa, C.E. Gallenga, S.K. Kritas, G. Ronconi, O. Trubiani, P. Conti, P.Di Emidio, E. Mazzon

Article ID: 4547
Vol 33, Issue 4, 2019
DOI: https://doi.org/10.54517/jbrha4547
Received: 22 May 2019; Accepted: 22 May 2019; Available online: 8 September 2019; Issue release: 8 September 2019

Abstract

Mesenchymal stem cells (MSCs) are able to exert immunomodulatory and anti-inflammatory actions. Thanks to these properties, MSCs may be a promising alternative approach for the treatment of inflammatory disease. Important cytokines involved in inflammation are those included in the IL-1 family. Interleukin-37 (IL-37) is one of the member able to suppress both innate and adaptive immunity. Recently, it was found that MSCs and their derivatives can modulate IL-37, and MSCs expressing IL-37 seem to have an enhanced therapeutic efficacy.


Keywords

mesenchymal stem cells;IL-37;inflammation


References

Supporting Agencies



Copyright (c) 2019 A. Gugliandolo, AL. Caraffa, C.E. Gallenga, S.K. Kritas, G. Ronconi, O. Trubiani, P. Conti, P.Di Emidio, E. Mazzon




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).